Spots Global Cancer Trial Database for malignant pleural mesothelioma
Every month we try and update this database with for malignant pleural mesothelioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | NCT05278975 | Malignant Pleur... Malignant Pleur... Mesothelioma Mesotheliomas P... Mesothelioma; L... Pleural Effusio... | RSO-021 | 18 Years - | RS Oncology LLC | |
| Alvopem® (Pemetrexed) Safety Assessment | NCT04843007 | Non Small Cell ... Malignant Pleur... | Pemetrexed | - | NanoAlvand | |
| Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | NCT04713761 | Malignant Pleur... | Toripalimab | 18 Years - 75 Years | Shanghai Pulmonary Hospital, Shanghai, China | |
| Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma | NCT05655078 | Malignant Pleur... | Proton beam the... | 18 Years - | University College, London | |
| SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | NCT04480372 | Malignant Pleur... Non-small Cell ... | Gemcitabine Atezolizumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma | NCT02269878 | Malignant Pleur... | 18 Years - | Ain Shams University | ||
| Nivolumab in Patients With Recurrent Malignant Mesothelioma | NCT02497508 | Malignant Pleur... | nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma | NCT00738582 | Malignant Pleur... | MORAb-009 (Amat... Pemetrexed Cisplatin | 18 Years - | Morphotek | |
| Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma | NCT00484276 | Malignant Pleur... | NGR-hTNF | 18 Years - | AGC Biologics S.p.A. | |
| Real World Study of MPM in China | NCT05042557 | Malignant Pleur... Diagnoses Disea... Treatments Prognosis | 18 Years - | ChineseAMS | ||
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | NCT04897022 | Malignant Pleur... | Pembrolizumab IMPRINT | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | NCT04334759 | Mesothelioma Pleural Mesothe... Malignant Pleur... | Durvalumab Standard Chemot... Ipilimumab and ... | 18 Years - | PrECOG, LLC. | |
| Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma | NCT03269227 | Malignant Pleur... | Accelerated hyp... | 18 Years - 85 Years | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | NCT01722149 | Malignant Pleur... | Adoptive Transf... | 18 Years - 75 Years | University of Zurich | |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | NCT05582031 | Anal Squamous C... Colorectal Neop... Soft Tissue Sar... Malignant Pleur... Small Cell Lung... Castrate Resist... Neuroendocrine ... Gastroenteropan... | Regorafenib in ... | 18 Years - | Translational Research in Oncology | |
| Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | NCT00165555 | Pleural Mesothe... Malignant Pleur... | Cisplatin Sodium Thiosulf... | 18 Years - | Dana-Farber Cancer Institute | |
| Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | NCT01644994 | Malignant Pleur... | intracavitary c... | 18 Years - | University of Zurich | |
| Autologous Dendritic Cell Vaccination in Mesothelioma | NCT02649829 | Malignant Pleur... | dendritic cell ... | 18 Years - | University Hospital, Antwerp | |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | NCT02863055 | Malignant Pleur... | Nintedanib Placebo | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Intrapleural Gene Transfer for Pleural Mesothelioma | NCT01212367 | Malignant Pleur... | SCH 721015 SCH 721015 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | NCT02397928 | Malignant Pleur... | NovoTTF-100L de... Pemetrexed Cisplatin or Ca... | 18 Years - | NovoCure Ltd. | |
| Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | NCT00886028 | Malignant Pleur... | Liposomal doxor... Cisplatin | 18 Years - 80 Years | National Institute of Cancerología | |
| Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | NCT00700336 | Malignant Pleur... Solid Tumors | pemetrexed, cis... pemetrexed and ... pemetrexed, cis... | 18 Years - | CanBas Co. Ltd. | |
| Malignant Mesothelioma - Can we Improve Quality of Life | NCT03068117 | Mesothelioma, M... | Regular Early S... | 18 Years - | Portsmouth Hospitals NHS Trust | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| APG-2449 in Patients With Advanced Solid Tumors | NCT03917043 | Advanced Solid ... Non Small Cell ... Esophageal Canc... Ovarian Cancer Malignant Pleur... | APG-2449 | 18 Years - | Ascentage Pharma Group Inc. | |
| APG-2449 in Patients With Advanced Solid Tumors | NCT03917043 | Advanced Solid ... Non Small Cell ... Esophageal Canc... Ovarian Cancer Malignant Pleur... | APG-2449 | 18 Years - | Ascentage Pharma Group Inc. | |
| Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma | NCT00272558 | Malignant Pleur... | Carboplatin and... | 18 Years - 85 Years | Rigshospitalet, Denmark | |
| A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | NCT02347917 | Malignant Pleur... Non-Small Cell ... | BBI608 Pemetrexed Cisplatin | 20 Years - | Sumitomo Pharma Co., Ltd. | |
| Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) | NCT05308966 | Malignant Pleur... Unresectable Ma... | Data collection | 18 Years - | Groupe Francais De Pneumo-Cancerologie | |
| Autologous Dendritic Cell Vaccination in Mesothelioma | NCT02649829 | Malignant Pleur... | dendritic cell ... | 18 Years - | University Hospital, Antwerp | |
| NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | NCT01098266 | Malignant Pleur... | NGR-hTNF plus B... Placebo plus Be... | 18 Years - | AGC Biologics S.p.A. | |
| A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | NCT04897022 | Malignant Pleur... | Pembrolizumab IMPRINT | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | NCT01870609 | Malignant Pleur... | defactinib (VS-... Placebo | 18 Years - | Verastem, Inc. | |
| Response Evaluation in Malignant Pleural Mesothelioma | NCT00969098 | Malignant Pleur... | 18 Years - | Istituto Clinico Humanitas | ||
| A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma | NCT01279967 | Malignant Pleur... | ADI-PEG 20 | 18 Years - | Barts & The London NHS Trust | |
| Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | NCT01722149 | Malignant Pleur... | Adoptive Transf... | 18 Years - 75 Years | University of Zurich | |
| The IMmunotherapy Pleural 5-ALA PDT | NCT04400539 | Mesotheliomas P... Malignant Pleur... | intrapleural ph... Nivolumab Injec... | 18 Years - | University Hospital, Lille | |
| ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) | NCT02194231 | Malignant Pleur... | Trabectedin | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | NCT04162015 | Malignant Pleur... | Nivolumab Pemetrexed Cisplatin or Ca... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma | NCT05005429 | Mesothelioma; L... | Bintrafusp alfa | 18 Years - | Fundación GECP | |
| Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | NCT02611037 | Malignant Pleur... Mesothelioma | Cisplatin Methotrexate Gemcitabine Lung Cancer Sym... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. | NCT01721018 | Malignant Pleur... | HSV1716 Intra-p... | 18 Years - | Virttu Biologics Limited | |
| Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | NCT04525859 | Malignant Pleur... | Safety Expansion Cohor... | - | Oncovir, Inc. | |
| Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma | NCT03048474 | Malignant Pleur... | nivolumab and i... | 18 Years - | The Netherlands Cancer Institute | |
| Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | NCT02397928 | Malignant Pleur... | NovoTTF-100L de... Pemetrexed Cisplatin or Ca... | 18 Years - | NovoCure Ltd. | |
| Autologous Redirected RNA Meso-CIR T Cells | NCT01355965 | Malignant Pleur... | Autologous T ce... | 18 Years - | University of Pennsylvania | |
| Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | NCT03175172 | Malignant Pleur... | CRS-207 Pembrolizumab | 18 Years - | Aduro Biotech, Inc. | |
| Autologous Dendritic Cell Vaccination in Mesothelioma | NCT02649829 | Malignant Pleur... | dendritic cell ... | 18 Years - | University Hospital, Antwerp | |
| Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | NCT04525859 | Malignant Pleur... | Safety Expansion Cohor... | - | Oncovir, Inc. | |
| Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma | NCT00386815 | Malignant Pleur... | pemetrexed cisplatin | 20 Years - 75 Years | Eli Lilly and Company | |
| Dendritic Cell-based Immunotherapy in Mesothelioma | NCT00280982 | Malignant Pleur... | tumor lysate-lo... | 18 Years - | Erasmus Medical Center | |
| Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | NCT02004028 | Malignant Pleur... | VS-6063 | 18 Years - | Verastem, Inc. | |
| Diadem to Investigate the Activity and Safety of Durvalumab | NCT04115111 | Pleura Mesothel... | Durvalumab | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | NCT04823741 | Mesothelioma, M... Gene Abnormalit... Pleural Mesothe... | PLEURAL BIOCOLL... | 18 Years - 95 Years | Hospices Civils de Lyon | |
| Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma | NCT03710876 | Malignant Pleur... | rAd-IFN Celecoxib Oral ... Gemcitabine | 18 Years - | Trizell Ltd | |
| A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | NCT04897022 | Malignant Pleur... | Pembrolizumab IMPRINT | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma | NCT04462809 | Advanced Malign... | Talazoparib | 18 Years - | Hospices Civils de Lyon | |
| Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | NCT01143545 | Lung Cancer Esophageal Canc... Malignant Pleur... Sarcoma Thymic Carcinom... | Allogeneic Tumo... Celecoxib cyclophosphamid... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | NCT01024946 | Malignant Pleur... | everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | NCT04823741 | Mesothelioma, M... Gene Abnormalit... Pleural Mesothe... | PLEURAL BIOCOLL... | 18 Years - 95 Years | Hospices Civils de Lyon | |
| Response Evaluation in Malignant Pleural Mesothelioma | NCT00969098 | Malignant Pleur... | 18 Years - | Istituto Clinico Humanitas | ||
| MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | NCT02369198 | Malignant Pleur... Non-Small Cell ... | TargomiRs | 18 Years - | Asbestos Diseases Research Foundation | |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | NCT02863055 | Malignant Pleur... | Nintedanib Placebo | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | NCT00700336 | Malignant Pleur... Solid Tumors | pemetrexed, cis... pemetrexed and ... pemetrexed, cis... | 18 Years - | CanBas Co. Ltd. | |
| Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | NCT01675765 | Malignant Pleur... | Immunotherapy p... Immunotherapy w... | 18 Years - | Aduro Biotech, Inc. | |
| Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining | NCT00242723 | Malignant Pleur... Esophageal Canc... Lung Cancer NOS Thoracic Cancer... Cancers of Non ... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | NCT03175172 | Malignant Pleur... | CRS-207 Pembrolizumab | 18 Years - | Aduro Biotech, Inc. | |
| Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | NCT03177668 | Malignant Pleur... | YS110 | 20 Years - | Kissei Pharmaceutical Co., Ltd. | |
| A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | NCT04162015 | Malignant Pleur... | Nivolumab Pemetrexed Cisplatin or Ca... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab + Defactinib In Pleural Mesothelioma | NCT04201145 | Malignant Pleur... | Pembrolizumab Defactinib | 18 Years - | Dana-Farber Cancer Institute | |
| Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients | NCT01865045 | Malignant Pleur... | - | Istituto Clinico Humanitas | ||
| A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | NCT01486368 | Malignant Pleur... | PF-03446962 | 18 Years - | Canadian Cancer Trials Group | |
| OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | NCT05425576 | Malignant Pleur... | OT-101 | 18 Years - | Mateon Therapeutics | |
| The IMmunotherapy Pleural 5-ALA PDT | NCT04400539 | Mesotheliomas P... Malignant Pleur... | intrapleural ph... Nivolumab Injec... | 18 Years - | University Hospital, Lille | |
| Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | NCT00886028 | Malignant Pleur... | Liposomal doxor... Cisplatin | 18 Years - 80 Years | National Institute of Cancerología | |
| Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma | NCT05005429 | Mesothelioma; L... | Bintrafusp alfa | 18 Years - | Fundación GECP | |
| A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma | NCT01353482 | Malignant Pleur... | Cisplatin Pemetrexed Vorinostat Placebo | 18 Years - | University College, London |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
